Completed Genetics & Molecular Biology Digestion, Kidneys & Other Organs

Dermatology and Genetic Medicine: A multidisciplinary research initiative aimed at translating basic science discoveries in genetic skin disease into clinical application.

In plain English

AI plain-English summary

A University of Dundee team is sequencing the DNA of hundreds of patients with rare genetic skin disorders to find the exact mutations that cause them. This matters because genetic skin diseases are under-researched, and many patients lack a precise diagnosis or effective treatment. The team is also tackling common conditions like eczema by searching for new genetic variants that drive the disease, including in the notoriously difficult-to-sequence filaggrin gene. Beyond discovery, the researchers are building a drug discovery pipeline modelled on a biotech company: they plan to run 15 high-throughput screens to find small-molecule drugs that hit newly identified targets, with the goal of partnering at least two of those targets with a pharmaceutical company. If successful, this work could turn fundamental genetic insights into real therapies for patients who currently have none. It could also streamline the diagnosis of rare skin disorders through whole-exome sequencing, giving families a name for their child’s condition. The project is a deliberate bridge between fundamental science and clinical application—it is not pure curiosity-driven research, but it is not yet at the bedside either.

View original technical description
Dermatology is an under-resourced area of research, however, the University of Dundee has established a critical mass of internationally competitive researchers in genetic skin disease and cutaneous therapy development. This award will strengthen this multidisciplinary research centre and catalyze further clinically applicable research at the interface of genetics, dermatology and drug discovery. Specifically, a large collection of diverse monogenic disorders accumulated through a UK genoderma tology network will be analysed using whole exome sequencing approaches, informed by transcriptome analysis. Targeted sequence capture and next-generation sequencing of loci identified by genomewide association studies will discover new causative variants in eczema, in addition to streamlining analysis of the large, repetitive filaggrin gene. Our previous genetics work has identified a number of new therapy targets tractable by small molecule approaches, which will extended here. A profession ally-managed biotech-style cutaneous drug discovery portfolio will be developed (3 projects already initiated) and extended to run 15 high-throughput screens, supported by hit validation and early hit-to-lead chemistry, with the aim of taking at least 2 dermatology targets through to pharmaceutical partnering. Animal and cell-culture platforms for assessing cutaneous drug/siRNA delivery/efficacy will be established. This award will also strengthen our capacity for patient outreach and training of new investigators.

View the original record at the funder ↗

Researchers

William McLean (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Gene2Skin - Roadmap for advanced genetic engineering-based skin therapies
MICA: Delivering gene silencing therapy to the epidermis and ocular surface
Arthritis Research UK Centre of Excellence in the Genetics of the Rheumatic Diseases
Optical approaches to delineate novel signalling pathways in skin blistering disease
UK inheritd retinal dystrophy consortium - The genetic architecture of unsolved inherited retinal dystrophies.

Original classification

Strategic Award - Science

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.